US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...

HS2's story begins with a blank piece of paper.